Pharmacological spasticity treatment on cerebral palsy
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i2a103313Keywords:
Child, Cerebral Palsy, Muscle Spasticity/drug effects, Botulinum Toxin Type AAbstract
Spasticity is a movement disorder characterized by a velocity dependant tonic stretch reflex (muscle tone) increase as a result of the reflex’s hyper-excitability and as a component of the Upper Neuron Syndrome, extremely common to in many neuropathological conditions. In this article we will review the physiopathology of espasticidade and the main drugs used in its treatment.
Downloads
References
Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, (eds). Spasticity: disordered motor control. Chicago: Year Book; 1980. p. 485-94.
Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motor neuron lesion. In: Mayer NH, Simpson DM, (eds). Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York: We Move; 2002. p. 1-15.
Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11(3):153-61.
Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607-16.
Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79.
Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72(10):869-72.
Tilton AH, Maria BL. Consensus statement on pharmacotherapy for spasticity. J Child Neurol. 2001;16(1):66-7.
Damiano DL, Alter KE, Chambers H. New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy. Phys Med Rehabil Clin N Am. 2009;20(3):469-91.
Gracies JM, Elovic E, Zorowitz R, McGuire J, Simpson D. Traditional pharmacologic treatments for spasticity. Part I: local treatments. In: Brashear A, Mayer NH, (eds). Etiology, evaluation, management and the role of botulium toxin. New York: We Move; 2008, p. 57-78.
Tilton A. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2009;16(2):82-9.
Matthews DJ, Balaban B. Management of spasticity in children with cerebral palsy. Acta Orthop Traumatol Turc. 2009;43(2):81-6.
Brin IL, Kurenkov AL, Gotlib VIa. The use of sirdalud in cerebral palsy in children. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(10):30-3.
Papavasiliou AS. Management of motor problems in cerebral palsy: a critical update for the clinician. Eur J Paediatr Neurol. 2009;13(5):387-96.
Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Chaleat Valayer E, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10(5-6):215-25.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
